1228 — Canbridge Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.07bn
- HK$1.11bn
- CNY85.10m
Annual cashflow statement for Canbridge Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -846 | -1,077 | -483 | -379 | -443 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 630 | 449 | 57.7 | 33.1 | 110 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 47 | 25.6 | 123 | 39.1 | 183 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -152 | -587 | -281 | -278 | -122 |
| Capital Expenditures | -153 | -5.33 | -34.8 | -40.9 | -0.105 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0 | 131 | 0 | 14 | 14 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -153 | 126 | -34.8 | -26.9 | 13.9 |
| Financing Cash Flow Items | -6.24 | -33.1 | -16.1 | -2.13 | -1.45 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 679 | 854 | -20.7 | -28 | -18.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 347 | 385 | -295 | -326 | -127 |